[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute image

A Personalized CLL Vaccine: NeoVax with Inhye Ahn, MD Dana-Farber Cancer Institute

Adult CLL Chapter
event May 10, 2024 / 02:30PM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

This show will not be live-streamed. You can submit your questions in advance by April 25th by clicking the button "Notify when available." 

Learn from Inhye Ahn, MD of Dana-Farber Cancer Institute, about a personalized vaccine against CLL called NeoVax that is being administered in a clinical trial to CLL patients not yet eligible to start standard therapies (watch and wait community). What if all you needed for your CLL treatment was a vaccine? Learn how NeoVax works, how it is being administered, and other important insights into this breakthrough therapy. 

 

 

 

Schedule & Agenda

The panelist Jennifer Ahlstrom
Introduction
2:30 PM
Jennifer Ahlstrom

Jenny introduces the agenda of the event and featured speaker Dr. Inhye Ahn. 

The panelist Inhye Ahn, MD
Discussion with Dr. Inhye Ahn
2:35 PM
Inhye Ahn, MD

Jenny discusses the NeoVax clinical trial with Dr. Ahn and any pre-submitted patient questions. 

Speakers & Moderators

The panelist Inhye Ahn, MD
Inhye Ahn, MD
Boston, MA

Dr. Ahn is a member of the Faculty of Medicine at Dana-Farber Cancer Institute specializing in the care of patients with chronic lymphocytic leukemia (CLL). She earned her medical degree from Catholic University of Korea and completed residency at The Methodist Hospital in Houston, TX combined with laboratory research training at MD Anderson Cancer Center. She completed hematology/oncology fellowship training at the National Institutes of Health. Her research highlighted patterns and molecular mechanisms of resistance to BTK inhibitors and led to the development of a novel prognostic tool specific to CLL patients receiving targeted therapy. Her goal as an investigator is to develop innovative therapies and individualized care for patients with CLL.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom
Lehi, UT

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

newsletter icon

Get the latest thought leadership on your Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.